Cai Jing Wang·2026-02-28 08:07Core Viewpoint - Rongchang Biopharma reported a significant increase in revenue and profit for the fiscal year 2025, indicating a strong performance driven by key product sales and strategic partnerships [1] Financial Performance - The company achieved total operating revenue of 3.251 billion yuan, representing a year-on-year increase of 89.36% [1] - The net profit attributable to shareholders reached 709 million yuan, marking a turnaround from previous losses to profitability [1] Growth Drivers - The rapid growth in domestic sales of core products, Tai Tasi Pu and Vidi Xi Tuo Dan Kang, has become the main growth engine for the company's performance [1] - A significant licensing agreement with Vor Biopharma has led to a substantial increase in technology licensing revenue [1] Operational Efficiency - The company has improved its profitability efficiency through management optimization and process iteration, resulting in reduced unit costs and increased gross margins [1] - The sales expense ratio has also decreased significantly, contributing to the overall improvement in profitability [1]